Home Stock

Stock Research: Evolus

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Evolus

NMQ:EOLS US30052C1071
88
  • Value
    98
  • Growth
    35
  • Safety
    Safety
    60
  • Combined
    85
  • Sentiment
    79
  • 360° View
    360° View
    88
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Evolus, Inc. is a performance beauty company focused on cash-pay aesthetic medical products. It operates in the medical aesthetics industry with product categories including injectable neurotoxins (Jeuveau) and injectable hyaluronic acid gels (Evolysse). Jeuveau is available in the United States, Canada, and certain European markets, while Evolysse is available in the United States and Europe. In the last fiscal year, the company had a market cap of $599 millions, profits of $182 millions, revenue of $266 millions, and 332 employees.

more

ANALYSIS: With an Obermatt 360° View of 88 (better than 88% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Evolus are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for Evolus. The consolidated Value Rank has an attractive rank of 98, which means that the share price of Evolus is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 98% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 60. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 79. But the consolidated Growth Rank has a low rank of 35, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 65 of its competitors have better growth. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Market Pulse
Country USA
Industry Pharmaceuticals
Size Small
Website evolus.com
Index
NASDAQ
Evolus stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
98 4 65 43
Growth
35 81 87 97
Safety
Safety
60 9 13 6
Sentiment
79 90 54 76
360° View
360° View
88 33 59 64
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
41 95 54 31
Opinions Change
50 75 31 75
Pro Holdings
n/a 18 24 82
Market Pulse
100 89 89 40
Sentiment
79 90 54 76
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
98 4 65 43
Growth
35 81 87 97
Safety Safety
60 9 13 6
Combined
85 4 61 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
100 41 40 62
Price vs. Earnings (P/E)
97 4 100 16
Price vs. Book (P/B)
91 1 100 28
Dividend Yield
1 1 1 1
Value
98 4 65 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
65 87 89 79
Profit Growth
84 76 63 62
Capital Growth
28 45 43 83
Stock Returns
5 61 85 73
Growth
35 81 87 97
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
3 3 11 3
Refinancing
91 32 29 49
Liquidity
83 27 27 20
Safety Safety
60 9 13 6

Similar Stocks

Discover high‑ranked alternatives to Evolus and broaden your portfolio horizons.

Zimmer

NYQ:ZBH
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Resideo Technologies

NYQ:REZI
Country: USA
Industry: Building Products
Size: Large
Full Stock Analysis

Peabody Energy

NYQ:BTU
Country: USA
Industry: Coal & Consumable Fuels
Size: Large
Full Stock Analysis

Innoviva

NSQ:INVA
Country: USA
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The stock offers good value, safe financing, and positive sentiment. However, it has below-average growth expectations. It is well-suited for conservative buy-and-hold investors who prioritize stability and low valuation over growth.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews